Covered recipient · General Payments record
STEVEN DON FOLKERTH
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$209.13
14 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $209.13 | 14 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $70.87 | 5 |
| AstraZeneca Pharmaceuticals LP | $34.93 | 3 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.53 | 1 |
| Amgen Inc. | $18.52 | 1 |
| GlaxoSmithKline, LLC. | $16.23 | 1 |
| Novartis Pharmaceuticals Corporation | $16.18 | 1 |
| Amarin Pharma Inc. | $15.55 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.32 | 1 |
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
STEVEN DON FOLKERTH
NPI 1215985197 · CMS profile ID 10174
Allopathic & Osteopathic Physicians / Internal Medicine
BEAVERCREEK, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- STEVEN DON FOLKERTH, NPI 1215985197, CMS profile ID 10174, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–14 of 14 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1215985197?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
14 matching records · $209.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–14 of 14.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| PFIZER INC. | $12.23 | 04/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672411411 | CMS |
| Novartis Pharmaceuticals Corporation | $16.18 | 04/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 660184469 | CMS |
| PFIZER INC. | $21.84 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672414807 | CMS |
| GlaxoSmithKline, LLC. | $16.23 | 04/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670758207 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.25 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685912095 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.32 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700384781 | CMS |
| PFIZER INC. | $11.10 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672459700 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.33 | 03/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685825127 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.53 | 02/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684726579 | CMS |
| Amarin Pharma Inc. | $15.55 | 02/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 699077641 | CMS |
| Amgen Inc. | $18.52 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 663075691 | CMS |
| PFIZER INC. | $14.63 | 02/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672415411 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.35 | 02/02/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685601573 | CMS |
| PFIZER INC. | $11.07 | 01/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672461767 | CMS |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2019 | $209.13 | 14 |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019
- Generated from
- OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $8,820.08 | 1 |
| PY2024 | Principal investigator | $75,861.80 | 1 |
| PY2023 | Principal investigator | $369,654.75 | 14 |
| PY2022 | Recipient | $202.26 | 1 |
| PY2022 | Principal investigator | $2,132,299.27 | 89 |
| PY2021 | Principal investigator | $5,447,139.77 | 65 |
| PY2020 | Principal investigator | $527,432.45 | 9 |
| PY2019 | Principal investigator | $510,064.93 | 30 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
65 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $70.00 | 12/31/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A PHASE 2B, 12-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF JZP385 IN THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ESSENTIAL TREMOR | No dispute reported | 06/30/2026 | 838143819 |
| Principal investigator 1 | Innocoll Incorporated | $472,314.00 | 12/22/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | No dispute reported | 06/30/2026 | 808594463 |
| Principal investigator 1 | Innocoll Incorporated | $3,500.00 | 12/22/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | No dispute reported | 06/30/2026 | 808594465 |
| Principal investigator 1 | Innocoll Incorporated | $2,500.00 | 12/22/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | No dispute reported | 06/30/2026 | 808594467 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,010.00 | 12/22/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PROOF OF CONCEPT PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-951 VERSUS ONDANSETRON IN THE PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING IN HIGH-RISK SUBJECTS | No dispute reported | 06/30/2026 | 816789509 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,750.00 | 12/22/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PROOF OF CONCEPT PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-951 VERSUS ONDANSETRON IN THE PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING IN HIGH-RISK SUBJECTS | No dispute reported | 06/30/2026 | 816789515 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/17/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | No dispute reported | 06/30/2026 | 793116063 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $10,000.00 | 12/14/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763833 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $2,082.00 | 12/14/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763845 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $18,226.00 | 12/10/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | Not supplied | No dispute reported | 06/30/2026 | 768161726 |
| Principal investigator 1 | Innocoll Incorporated | $650,412.00 | 11/26/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | No dispute reported | 06/30/2026 | 808594429 |
| Principal investigator 1 | Innocoll Incorporated | $2,352.00 | 11/26/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | No dispute reported | 06/30/2026 | 808594431 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $569.00 | 11/16/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763821 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $1,257.22 | 11/12/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768161358 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $1,460.00 | 11/05/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | Not supplied | No dispute reported | 06/30/2026 | 768161502 |
| Principal investigator 1 | Eli Lilly and Company | $2,250.00 | 11/01/2021 | Non-covered Recipient Entity ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC | A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 | No dispute reported | 06/30/2026 | 819459933 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $780.00 | 10/29/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | No dispute reported | 06/30/2026 | 793112889 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,576.25 | 10/29/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793112891 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $750.00 | 10/29/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793112893 |
| Principal investigator 1 | Vertex Pharmaceuticals Incorporated | $247,202.60 | 10/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Phase 2 randomized double blind placebo controlled study evaluating the efficacy and safety of VX-548 for acute pain after an abdominoplasty | No dispute reported | 06/30/2026 | 793094495 |
| Principal investigator 1 | Innocoll Incorporated | $468,153.60 | 10/25/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | No dispute reported | 06/30/2026 | 808594405 |
| Principal investigator 1 | Innocoll Incorporated | $39,554.40 | 10/25/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | No dispute reported | 06/30/2026 | 808594407 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $194.69 | 10/19/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763799 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $219.00 | 10/19/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763809 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $1,000.00 | 10/11/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768161394 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $324,665.55 | 10/08/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793111607 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $314.08 | 10/08/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | Not supplied | No dispute reported | 06/30/2026 | 768162974 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $6,008.00 | 09/28/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763723 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $180,413.65 | 09/09/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | No dispute reported | 06/30/2026 | 793096881 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $2,075.00 | 09/07/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | Not supplied | No dispute reported | 06/30/2026 | 768161398 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $858.75 | 09/03/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793109349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $82,415.00 | 08/27/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793109105 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38,200.00 | 08/27/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | No dispute reported | 06/30/2026 | 793109107 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10,500.00 | 08/27/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | No dispute reported | 06/30/2026 | 793109109 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $167,853.60 | 08/27/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793109111 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,434.00 | 08/27/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | No dispute reported | 06/30/2026 | 793109113 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $30,105.40 | 08/27/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768161020 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $13,478.30 | 08/27/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768161022 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $840.00 | 08/20/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers | No dispute reported | 06/30/2026 | 793108561 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $5,669.00 | 08/17/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763785 |
| Principal investigator 1 | Innocoll Incorporated | $361,629.60 | 07/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | No dispute reported | 06/30/2026 | 808594347 |
| Principal investigator 1 | Innocoll Incorporated | $7,000.00 | 07/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | No dispute reported | 06/30/2026 | 808594349 |
| Principal investigator 1 | Innocoll Incorporated | $7,500.00 | 07/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | No dispute reported | 06/30/2026 | 808594351 |
| Principal investigator 1 | Innocoll Incorporated | $7,000.00 | 07/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | No dispute reported | 06/30/2026 | 808594353 |
| Principal investigator 1 | Innocoll Incorporated | $7,500.00 | 07/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | No dispute reported | 06/30/2026 | 808594355 |
| Principal investigator 1 | Innocoll Incorporated | $139,472.40 | 07/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty | No dispute reported | 06/30/2026 | 808594357 |
| Principal investigator 1 | Innocoll Incorporated | $182,838.00 | 07/29/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty | No dispute reported | 06/30/2026 | 808594359 |
| Principal investigator 1 | Heron Therapeutics, Inc. | $1,200.00 | 07/22/2021 | Non-covered Recipient Entity ERG Holding Company | A Phase 4, Open-Label Study of Liposomal Bupivacaine Admixed With Bupivacaine HCl in Subjects Undergoing Total Knee Arthroplasty | No dispute reported | 06/30/2026 | 782091461 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $18,750.00 | 07/19/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, Efficacy, and Immunogenicity of V590 rVSV G-SARS-CoV-2-S, Live in Healthy Individuals 16 Years of Age or Older | No dispute reported | 06/30/2026 | 848761161 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $7,586.00 | 07/13/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763775 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $20,579.85 | 07/12/2021 | Non-covered Recipient Entity ERG HOLDING | Not supplied | No dispute reported | 06/30/2026 | 768161138 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $833,133.60 | 06/25/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793104981 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $1,800.00 | 06/15/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763765 |
| Principal investigator 1 | Eli Lilly and Company | $4,108.48 | 05/26/2021 | Non-covered Recipient Entity ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC | A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 | No dispute reported | 06/30/2026 | 819457563 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $3,500.00 | 05/18/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763753 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $38,200.00 | 04/30/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793101843 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $2,900.00 | 04/13/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763743 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $46,561.40 | 03/12/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768160720 |
| Principal investigator 1 | Heron Therapeutics, Inc. | $51,505.05 | 03/04/2021 | Non-covered Recipient Entity ERG Holding Company | A Phase 4, Open-Label Study of Liposomal Bupivacaine Admixed With Bupivacaine HCl in Subjects Undergoing Total Knee Arthroplasty | No dispute reported | 06/30/2026 | 782091457 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $70,907.00 | 02/26/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793097469 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $647,149.50 | 02/26/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC | A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF REPEATED SUBCUTANEOUS DOSES OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES (REGN10933+REGN10987) IN ADULT VOLUNTEERS | No dispute reported | 06/30/2026 | 793097485 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $136,008.30 | 02/16/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768160718 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $22,500.00 | 02/16/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768160722 |
| Principal investigator 1 | Siemens Medical Solutions USA, Inc. | $8,662.50 | 02/16/2021 | Non-covered Recipient Entity ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL | Not supplied | No dispute reported | 06/30/2026 | 768160724 |
| Principal investigator 1 | Endo Pharmaceuticals Inc. | $7,000.00 | 01/19/2021 | Non-covered Recipient Entity MIDWEST CLINICAL RESEARCH CENTER LLC | An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products | No dispute reported | 06/30/2026 | 830763733 |